A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1

Cancer Gene Therapy

Volumn 7, Issue 3, 2000, Pages 466-475

  Stuart, Darrin D ^a   Kao, Grace Y ^b   Allen, Theresa M ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Urigen Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antisense oligodeoxynucleotides; Biodistribution; Gene therapy; Multidrug resistance; Pharmacokinetics; Targeted liposomes

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; IODINE 125; LIPOSOME; PHOSPHOROTHIOIC ACID;

ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG FORMULATION; FEMALE; GENE TARGETING; GENE THERAPY; ISOTOPE LABELING; LYMPHOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0034033621     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700145     Document Type: Article

References (55)

1. Stein CA, Cheng YC. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven Publishers; 1997:3059-3074.
2. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents: is the bullet really magic? Science. 1993; 261:1004-1012.
3. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 1996;2:668-675.
4. Ratajczak MZ, Kant JA, Luger SM, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA. 1992;89:11823-11827.
5. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 1996;56:4332-4337.
6. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
7. Weiss B, Zhou LW, Zhang SP, Qin ZH. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA. Neuroscience. 1993;55:607-612.
8. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 1993;259:528-531.
9. Zhang SP, Zhou LW, Weiss B. Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J Pharmacol Exp Ther. 1994;271:1462-1470.
10. Antisense '97: a roundtable on the state of the industry. Nat Biotechnol. 1997;15:519-524.
11. Bennett CF, Chiang M, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1992;41:1023-1033.
12. Feigner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987;84:7413-7417.
13. Zuidam NJ, Barenholz Y. Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta. 1998;1368:115-128.
14. Bennett CF, Zuckerman JE, Kornbrust D, et al. Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J Controlled Release. 1996;41:121-130.
15. Litzinger DC, Brown JM, Wala I, et al. Fate of liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1996;1281:139-149.
16. Maruyama K, Kennel SJ, Huang L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci USA. 1990;87: 5744-5748.
17. Debs RJ, Heath TD, Papahadjopoulos D. Targeting of anti-Thy 1.1 monoclonal antibody-conjugated liposomes in Thy 1.1 mice after intravenous administration. Biochim Biophys Acta. 1987;901:183-190.
18. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
19. Reimer DL, Zhang YP, Kong S, et al. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry. 1995;34:12877-12883.
20. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA. 1978;75:4194-4198.
21. Ohkawa T, Kijima H, Irie A, et al. In: Gupta S, Tsuruo T, eds. Multidrug Resistance in Cancer Cells. Chichester, NY: John Wiley & Sons; 1996:413-433.
22. Piatyszek MA, Jarmolowski A, Augustyniak J. Iodo-gen mediated radioiodination of nucleic acids. Anal Biochem. 1988;172:356-359.
23. Commerford SL. Iodination of nucleic acids in vitro. Biochemistry. 1971;10:1993-2000.
24. Thierry AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioated, and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 1992;20:5691-5698.
25. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta. 1979;557:9-23.
26. 125I-labeled inulin: a convenient marker for deposition of liposomal contents in vivo. Biochem Biophys Res Commun. 1984;122: 319-324.
27. Wong FMP, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry. 1996;35:5756-5763.
28. Zola H, Macardle PJ, Bradford T, et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol. 1991;69:411-422.
29. Allen TM. In: Lopez-Berestein G, Fidler I, eds. UCLA Symposium on Molecular and Cellular Biology. New York: Alan R. Liss; 1988:405-415.
30. Allen TM, Hansen CB, Lopes de Menezes DE. Pharmacokinetics of long-circulating liposomes. Adv Drug Delivery Rev. 1995;16:267-284.
31. Cohen D, Yang CP, Horwitz SB. The products of the mdr1a and mdr1b genes from multidrug-resistant murine cells have similar degradation rates. Life Sci. 1990;46:489-495.
32. Muller C, Laurent G, Ling V. P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol. 1995;163:538-544.
33. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996;7:568-578.
34. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235-237.
35. Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with the poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1991;1062:77-82.
36. Allen TM, Hansen CB, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991;1066:29-36.
37. Poste G. Liposome targeting in vivo: problems and opportunities. Biol Cell. 1983;47:19-38.
38. Allen TM, Hansen CB. Pharmacokinetics of Stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068:133-141.
39. Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995;28:7-16.
40. De Long RK, Nolting A, Fisher M, et al. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 1997;7:71-77.
41. Tonkinson JL, Stein CA. Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Invest. 1996;14:54-65.
42. Bayever E, Iversen PL, Bishop MR, et al. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993;3:383-390.
43. Hong K, Zheng W, Baker A, Papahadjopoulos D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett. 1997; 400:233-237.
44. Templeton N, Lasic D, Frederik PM, et al. Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-652.
45. Scheule RK, St George JA, Bagley RG, et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther. 1997;8:687-707.
46. Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997; 1329:345-356.
47. Black CD, Gregoriadis G. Interactions of liposomes with blood plasma proteins. Biochem Soc Trans. 1976;4:253-256.
48. Litzinger DC. Limitations of cationic liposomes for antisense oligonucleotide delivery in vivo. J Liposome Res. 1997;7:51-61.
49. Northfelt DW, Martin FJ, Kaplan LD, et al. Pharmacokinetics, tumour localization, and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. Proc Am Soc Clin Oncol. 1993;12:51.
50. Working PK, Newman MS, Huang SK, et al. Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J Liposome Res. 1994;4:667-687.
51. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998;58:3320-3330.
52. Trambas CM, Muller HK, Woods GM. P-glycoprotein-mediated multidrug resistance and its implications for pathology. Pathology. 1997;29:122-130.
53. Essodaigui M, Broxterman HJ, Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry. 1998;37:2243-2250.
54. Albrecht T, Schwab R, Peschel C, et al. Cationic lipid-mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects, and modulation of gene expression. Ann Hematol. 1996;72:73-79.
55. Williams SA, Chang L, Buzby JS, Suen Y, Cairo MS. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma. Leukemia. 1996;10:1980-1989.